Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 10;38(29):3388-3397.
doi: 10.1200/JCO.20.00549. Epub 2020 Aug 4.

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León-Castillo  1 , Stephanie M de Boer  2 , Melanie E Powell  3 , Linda R Mileshkin  4 , Helen J Mackay  5 , Alexandra Leary  6 , Hans W Nijman  6   7 , Naveena Singh  8 , Pamela M Pollock  9 , Paul Bessette  10 , Anthony Fyles  11 , Christine Haie-Meder  12 , Vincent T H B M Smit  1 , Richard J Edmondson  13 , Hein Putter  14 , Henry C Kitchener  13 , Emma J Crosbie  13 , Marco de Bruyn  7 , Remi A Nout  2 , Nanda Horeweg  2 , Carien L Creutzberg  2 , Tjalling Bosse  1 ; TransPORTEC consortium
Affiliations

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León-Castillo et al. J Clin Oncol. .

Abstract

Purpose: The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants.

Methods: Paraffin-embedded tissues of 423 consenting patients were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for POLE exonuclease domain were done to classify tumors as p53 abnormal (p53abn), POLE-ultramutated (POLEmut), MMR-deficient (MMRd), or no specific molecular profile (NSMP). The primary end point was recurrence-free survival (RFS). Kaplan-Meier method, log-rank test, and Cox model were used for analysis.

Results: Molecular analysis was successful in 410 high-risk EC (97%), identifying the 4 subgroups: p53abn EC (n = 93; 23%), POLEmut (n = 51; 12%), MMRd (n = 137; 33%), and NSMP (n = 129; 32%). Five-year RFS was 48% for patients with p53abn EC, 98% for POLEmut EC, 72% for MMRd EC, and 74% for NSMP EC (P < .001). The 5-year RFS with CTRT versus RT for p53abn EC was 59% versus 36% (P = .019); 100% versus 97% for patients with POLEmut EC (P = .637); 68% versus 76% (P = .428) for MMRd EC; and 80% versus 68% (P = .243) for NSMP EC.

Conclusion: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as well as in future trials to target specific subgroups of patients.

Trial registration: ClinicalTrials.gov NCT00411138.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Flowchart of sample analysis. EC, endometrial cancer; FFPE, formalin-fixed, paraffin-embedded; NOS, not otherwise specified; PORTEC-3, Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer.
FIG 2.
FIG 2.
Kaplan-Meier survival curves for 5-year (A) recurrence-free survival (RFS) for patients with p53abn endometrial cancer (EC; 48.0%), POLEmut EC (98.0%), MMRd (71.7%), or NSMP EC (74.4%), and (B) overall survival (OS) in patients with p53abn EC (54.0%), POLEmut EC (98.0%), MMRd (81.3%), or NSMP EC (88.5%). MMRd, MMR-deficient; NSMP, no specific molecular profile; p53abn, p53-abnormal; POLEmut, POLE-ultramutated.
FIG 3.
FIG 3.
Kaplan-Meier survival curves for (A) recurrence-free survival (RFS) and (B) overall survival (OS) among patients with p53abn endometrial cancer (EC); (C) RFS and (D) OS among patients with POLEmut EC; (E) RFS and (F) OS among patients with MMRd EC; and (G) RFS and (H) OS among patients with NSMP EC. CTRT, combined adjuvant chemotherapy and radiotherapy; HR, hazard ratio; MMRd, MMR-deficient; NSMP, no specific molecular profile; p53abn, p53-abnormal; Pcox, P value by Cox regression analysis; POLEmut, POLE-ultramutated tumor; RT, external beam radiotherapy alone.
See this image and copyright information in PMC

References

    1. Levine DAKandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma Nature 49767–73.2013[Erratum: Nature 500:242, 2013] - PMC - PubMed
    1. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113:299–310. - PMC - PubMed
    1. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22:4215–4224. - PubMed
    1. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802–813. - PubMed
    1. Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29:1180–1188. - PubMed

Publication types

MeSH terms

Associated data